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Outcomes From a Minority-Based Lung Cancer Screening Program vs the National Lung Screening Trial
The National Lung Screening Trial (NLST) showed a 20% reduction in lung cancer (LC) mortality by detection of LC at an early stage with low-dose computed tomography (LDCT) scanning vs chest radiography for individuals who are at high-risk for LC based largely on age and smoking history.
1 A total of 90.9% of the NLST participants were white, and only 4.5% were African American. Yet, although the overall incidence and mortality from LC have been declining in the United States, African Americans have the highest LC mortality rate compared with other races. The magnitude of this racial disparity has increased over the past 4 decades. 2 Screening programs tailored to high-risk patients of minority races/ethnicities could help to reduce this health disparity and save even more lives. 3 The goal of this study was to assess the demographic characteristics, baseline LDCT scan findings (lung reporting and data system, Lung-RADS 4 ), and detected LCs in an inner city, minority-based population at the University of Illinois at Chicago (UIC) that included federally qualified health centers vs that of the NLST.
Methods | We performed a retrospective analysis of the first 500 baseline LDCT screens at UIC and evaluated these data against the NLST LDCT (26 722 baseline screens) arm. The study was conducted from September 4, 2015, to December 28, 2017. Inclusion criteria for the UIC cohort were the same as in the NLST study. 1 We compared UIC LDCT findings with those of the NLST using Lung-RADS criteria that were established by the American College of Radiology in 2015 and retrospectively applied to the NLST in a secondary analysis (26 455 evaluable). 4 Lung-RADS is now in common use as a system for risk stratifying and standardizing LDCT findings on a scale of 0 to 4 primarily based on the presence and/or characteristics of lung nodules. Demographic data, Lung-RADS scores of baseline LDCT scans, and diagnosed LC cases were collected and evaluated vs data of the NLST LDCT arm. Summary statistics and statistical tests (2-tailed, unpaired t tests for continuous variables and χ 2 tests for categorical variables) were applied to compare the UIC cohort with the NLST LDCT arm. The study was approved by the UIC Institutional Review Board. Statistical analysis was performed using SAS, version 9.4 (SAS Institute Inc).
Results | Demographic characteristics of the UIC cohort did not resemble those of the NLST LDCT arm ( 
Assessment of the Accuracy of Disease Coding Among Patients Diagnosed With Sarcoma
The rarity of sarcoma makes performing appropriately powered studies challenging and increases the significance of accurate data collection. Tumor registries and population-based databases are increasingly used to determine sarcoma incidence, treatment patterns, and outcomes. [1] [2] [3] The utility of these databases is contingent on meticulous data collection. Although the validity of large databases has been questioned, 4 little is documented about the initial coding process. This study characterizes inaccuracies in coding practices that result in incorrect sarcoma surgical diagnostic codes and tumor registry data at a high-volume health care center. Identification of coding practice errors has implications for the validity of larger oncology databases. Results | During the study period, 2715 patients with soft-tissue and bone oncologic cases were treated by 3 surgical oncologists (1856 cases) and 2 orthopedic oncologists (859 cases). Of these, 1237 patients (855 treated by surgical oncologists, 382 treated by orthopedic oncologists) had a sarcoma diagnosis confirmed by pathologic findings.
On the basis of ICD-9 and ICD-10 codes, 764 of 1237 patients (61.8%) had cases that were accurately coded as sarcoma, 208 of 1237 patients (16.8%) had a nononcologic diagnosis, and 265 of 1237 patients (21.4%) had an organ sitebased malignancy code; 487 of 855 patients (57.0%) treated by surgical oncologists and 277 of 382 patients (72.5%) treated by orthopedic oncologists had cases that were accurately coded. Organ-confined sarcoma was commonly coded with a nonsarcoma, organ-site ICD-9 or ICD-10 code (Table) . For instance, 49 of 156 (31.4%) gastric gastrointestinal stromal tumor cases and 24 of 46 (52.2%) breast angiosarcoma cases were coded as gastric and breast cancer, respectively (Figure) .
Based on ICD-O-3 codes from the Dana-Farber Cancer Institute tumor registry during an overlapping 4-year period, 631 of 1055 patients (59.8%) had cases that were accurately coded, 
